Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
W. Gan (Tianjin, China), K. Huang (Tianjin, China), Z. Lv (Tianjin, China), S. Gao (Tianjin, China), C. Su (Tianjin, China), X. Li (Tianjin, China), H. Zhou (Tianjin, China). Comparison of in-vitro anti-fibrotic effects of pirfenidone and nintedanib. 1282

Member's Comments

No comment yet.

Related content which might interest you: Comparison of in-vivo anti-fibrotic effects of pirfenidone and nintedanib in bleomycin-induced pulmonary fibrosis model Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Antifibrotic activities of pirfenidone in animal models Source: Eur Respir Rev 2011; 20: 85-97 Year: 2011 The combination of budesonide and formoterol exerts more rapid and enhanced anti-inflammatory effects than either drug alone in rat lungs in vivo Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004 Preclinical anti-inflammatory activity and safety profile of the novel glucocorticoid ciclesonide Source: Eur Respir J 2001; 18: Suppl. 33, 147s Year: 2001 Effect of sildenafil add-on to antifibrotic treatment in IPF patients Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Anti-inflammatory and anti-fibrotic effects of sirolimus in bleomycin-induced pulmonary fibrosis in rats Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 Persistency of antioxidant/antiinflammatory effects of erdosteine treatment in COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 No relevant pharmacokinetic drug–drug interaction between nintedanib and pirfenidone Source: Eur Respir J, 53 (1) 1801060; 10.1183/13993003.01060-2018 Year: 2019 Anti-inflammatory, antioxidant and immunomodulatory effects of curcumin in sensitized rat Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017 Efficacy and tolerability of nintedanib switched from pirfenidone for IPF patients Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020 In vitro and in vivo anti-inflammatory activity of the novel PDE4 inhibitor roflumilast Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 HDAC2-independent anti-inflammatory effects of budesonide in human lung fibroblasts Source: Annual Congress 2011 - Recent developments in COPD Year: 2011 Anti-inflammatory effects of add-on atorvastatin therapy during the treatment of COPD patients Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2015; 45: 1382-1392 Year: 2015 Synergistic therapy for NSCLC: Additive preclinical efficacy of interleukin-6 inhibitor madindoline A with crizotinib Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Therapeutic effect of combination of salvia and ligustrazine on bleomycin-induced pulmonary fibrosis Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials Source: Eur Respir J, 53 (4) 1801655; 10.1183/13993003.01655-2018 Year: 2019 ‘Total PDE4 inhibitory activity‘: a concept for evaluating pharmacokinetic alterations of roflumilast and roflumilast N-oxide in special populations and drug-drug interactions Source: Eur Respir J 2006; 28: Suppl. 50, 436s Year: 2006